Free shipping on all orders over $ 500


Cat. No. M3001
SC144 Structure
Size Price Availability Quantity
5mg USD 50  USD50 In stock
10mg USD 85  USD85 In stock
25mg USD 170  USD170 In stock
50mg USD 280  USD280 In stock
100mg USD 450  USD450 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

SC144 is the first oral active GP130 (IL6-beta) inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, eliminates Stat3 phosphorylation and nuclear translocation, and further inhibits downstream target gene expression. SC144 inhibited signal transduction induced by GP130 ligand. SC144 induces apoptosis of human ovarian cancer cells.

Protocol (for reference only)
Cell Experiment
Cell lines OVCAR-8, OVCAR-5, OVCAR-3, Caov-3, SKOV-3, HEY NCI/ADR-RES
Preparation method MTT assay
Concentrations ~10 μM
Incubation time 96 h
Animal Experiment
Animal models Human Ovarian Cancer OVCAR-8 Xenograft
Formulation .9% NaCl with 40% propylene glycol
Dosages 10 mg/kg daily
Administration i.p. or p.o.
Chemical Information
Molecular Weight 322.3
Formula C16H11FN6O
CAS Number 895158-95-9
Form Solid
Solubility (25°C) DMSO 15 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Tiangong Lu, et al. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer

[2] Fedora Grande, et al. Identification and Preclinical Evaluation of SC144, a Novel Pyrroloquinoxaline Derivative with Broad-Spectrum Anticancer Activity

[3] Shili Xu, et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer

[4] Takashi Oshima, et al. Combination effects of SC144 and cytotoxic anticancer agents

[5] Carmen Plasencia, et al. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity

Related IL Receptor/Related Products

Ebdarokimab is a monoclonal antibody to IL-12p40/IL-23 that can be used in studies related to inflammatory bowel disease (IBD).


Brazikumab is a human IgG2 monoclonal antibody targeting IL-23 that selectively binds to the p19 subunit of IL-23 and has a KD value of 0.138 nM against human IL-23 for Crohn's disease (CD).


DC-806 is an orally active small molecule inhibitor of IL-17 for studies related to psoriasis.


JNJ-2113 is a novel, orally active IL-23R peptide inhibitor for studies related to plaque psoriasis.


PF-04236921 is a fully human IgG2 monoclonal antibody targeting the interleukin IL-6 for studies related to Crohn's disease and rheumatoid arthritis.

Abmole Inhibitor Catalog

Keywords: SC144 supplier, IL Receptor/Related, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.